INO <link back for chart> Good News HIV and FlU pathways- stock should gap up.
Inovio Pharmaceuticals' synthetic vaccines delivered with minimally invasive skin electroporation technology generate potent immune responses (INO) 0.59 : Co announces the publication of positive immunological effects in preclinical animal models of optimized electroporation parameters for its minimally invasive skin EP delivery devices in the peer-reviewed journal, Human Gene Therapy. The newly published optimized conditions for co's skin EP delivery systems will dramatically enhance this delivery system as an attractive method for mass vaccination by decreasing dose levels, increasing tolerability of the vaccination, and increasing the breadth of viable vaccine targets. The newly optimized conditions pave the path for more efficient delivery for co's universal flu vaccines as well as the HIV vaccines currently in testing in Phase I studies.